期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 176, 期 18, 页码 3515-3532出版社
WILEY
DOI: 10.1111/bph.14618
关键词
-
资金
- Medical Research Council [MR/M024962/1, MC_EX_MR/N50192X/1, MR/L023784/1, MC_PC_16034, MR/L023784/2] Funding Source: Medline
- Parkinson's UK [J-0901] Funding Source: Medline
- Wellcome Trust Funding Source: Medline
- MRC [MR/L023784/2, MR/M024962/1, MC_PC_16034, MC_EX_MR/N50192X/1, MR/L023784/1] Funding Source: UKRI
One of the largest unmet medical needs is a disease-modifying treatment for Alzheimer's disease (AD). Recently, the role of microglia in disease, particularly AD, has gained great interest, following the identification of several disease risk-associated genes that are highly expressed in microglia. Microglia play a critical homeostatic role in the brain, with neuroinflammatory and phagocytic mechanisms being of particular importance. Here, we review the role of NLRP3, the complement system, and the triggering receptor expressed in myeloid cells 2 (TREM2) in modulating microglial functions. We have reviewed the targets, their molecular pathways and the therapeutic interventions aimed at modulating these targets, in the hope of discovering a novel therapeutic approach for the treatment of AD. Linked Articles This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据